Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report (Q89700420)
Jump to navigation
Jump to search
scientific article published on 11 March 2016
Language | Label | Description | Also known as |
---|---|---|---|
English | Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report |
scientific article published on 11 March 2016 |
Statements
Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report (English)
Wen-Ying Zhang
Yao Wang
Ye-Lei Guo
Han-Ren Dai
Qing-Ming Yang
Ya-Jing Zhang
Yan Zhang
Mei-Xia Chen
Chun-Meng Wang
Kai-Chao Feng
Su-Xia Li
Yang Liu
Feng-Xia Shi
Can Luo
11 March 2016
1 reference